Soluble immune checkpoints CD27, Lag3, PD-L2 and Tim3 in early stage NSCLC patients

      Rational: Within the evolving area of immune checkpoint inhibitory therapies predictive biomarkers are still rare and intricate in clinical routine, even though they are highly warranted to improve patient outcome and cost effectiveness.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect